All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

ADORA - A randomised controlled trial to evaluate anticoagulant cessation after antiphospholipid autoantibodies loss in thrombotic antiphospholipid syndrome

Antiphospholipid syndrome (APS) is an immune condition that makes blood more likely to clot. People with APS usually take lifelong blood-thinning tablets to prevent future clots. However, in some people, the harmful antibodies that cause the condition fade away over time. This clinical trial is called ADORA. It is testing whether people whose antibodies have disappeared can safely stop taking their blood thinners. Taking blood thinners prevents clots, but it can also cause serious bleeding problems and requires regular checks. Participants will either stop their blood thinners or carry on taking them as normal. Doctors will closely track both groups to see if blood clots return, monitor any bleeding problems, check if antibodies come back, and see how quality of life changes. This study aims to help doctors give clear, safe advice about stopping medication in the future.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Assistance Publique Hopitaux De Paris
Enrolment target
234
Start
12 Nov 2026

What is this study about?

Antiphospholipid syndrome, or APS, is sometimes called 'sticky blood syndrome'. In APS, the immune system makes unusual proteins called antibodies that attack healthy tissues, making harmful blood clots much more likely to form in veins or arteries. To prevent these dangerous clots, most people are prescribed long-term blood-thinning tablets, such as warfarin.

Doctors have noticed that in some patients, these harmful antibodies can naturally drop to normal levels or disappear completely over time. When this happens, patients and doctors face a difficult choice. Staying on blood thinners protects against clots, but it brings a daily risk of bleeding, requires dietary care, and often means frequent blood monitoring tests. Stopping the medicine removes the bleeding risk, but no one knows for certain if the risk of blood clots returns once the tablets are stopped.

The ADORA study was designed to answer this important question. It compares what happens when people with clear antibody tests stop their blood thinners against what happens when they stay on them. By gathering strong evidence, the study aims to find out if stopping medication is truly safe, helping future patients avoid unnecessary treatments while staying protected.

Key takeaways

  • The ADORA study tests whether people with APS can safely stop blood thinners after their antibodies disappear.
  • Participants are randomly assigned to either stop taking their blood thinners or keep taking them.
  • Doctors will closely monitor participants for any signs of new blood clots or bleeding problems.
  • The findings will help doctors give clearer advice to future patients about whether lifelong medication is truly needed.
  • Taking part is voluntary, and you can leave the study at any time.

Who may be eligible?

This trial is open to adults aged 18 and older who were previously diagnosed with thrombotic APS (meaning they had at least one blood clot caused by the condition).

To be considered, you must currently have a low-risk health profile and your routine blood tests must show that your antiphospholipid antibodies have disappeared or returned to normal levels.

Because this study looks at a very specific group, people who still have high levels of these antibodies or who have other major health issues that require them to take blood thinners will not be able to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with antiphospholipid syndrome (APS).
  3. I have had a blood clot in the past caused by APS.
  4. I currently take a blood-thinning medicine (such as warfarin).
  5. Recent blood tests show my antiphospholipid antibodies have cleared or are now normal.
Answer every question to see your result.

What does participation involve?

If you decide to join the study, you will be placed into one of two groups by chance (like flipping a coin). One group will carefully stop taking their blood-thinning tablets, while the other group will continue taking their usual blood thinners.

Throughout the study, you will have regular hospital check-ups and routine blood tests. Doctors will monitor your blood to see if your antibody levels change, check your overall health, and ask you to fill out short quality-of-life questionnaires to see how you are feeling day-to-day.

You will be followed up closely over an extended period. If at any point you develop symptoms of a clot, abnormal bleeding, or if your antibodies return, the medical team will review your treatment immediately.

Potential risks and benefits

A potential benefit of stopping blood thinners is a reduced risk of bruising and serious bleeding, as well as the freedom from regular blood-monitoring clinic visits. A potential risk is that blood clots could return once the medicine is stopped. For those who stay on their tablets, the main risk remains the ongoing chance of bleeding. Joining this study is entirely your choice, and you can withdraw at any time without your normal NHS care or relationship with your doctor being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France

Common questions

What is the main goal of the ADORA trial?

The study aims to see if it is safe for people with antiphospholipid syndrome to stop taking blood thinners once their harmful antibodies have gone away.

Can I choose whether I stop taking my blood thinners?

No. A computer will randomly decide whether you stop your medicine or stay on it, ensuring the trial results are fair and reliable.

What happens if my antibodies come back during the study?

Doctors will test your blood regularly. If the antibodies reappear, the study team will review your situation and can restart your blood thinners to protect your health.

Will taking part affect my everyday life?

You will need to attend hospital visits for check-ups and blood tests, and complete short questionnaires about your wellbeing, but your daily routine should otherwise remain mostly the same.

Can I leave the study if I change my mind?

Yes. You can leave the trial at any point, for any reason, and your medical team will discuss the best ongoing treatment plan for you.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.